Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Seipel

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Molecular Cancer Therapeutics|July 25, 2015
Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal CancerMeera Raja, Matt Zverev, Katja Seipel, et al.
Cancers|January 21, 2023
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple MyelomaSelina Bühler, Dilara Akhoundova, Barbara Jeker, et al.
British Journal of Haematology|September 13, 2014
Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemiaDana Wetzel, Beatrice U Mueller, Behrouz Mansouri Taleghani, et al.
Cancers|May 14, 2025
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma PatientsLea Jasmin Kündgen, Dilara Akhoundova, Michele Hoffmann, et al.
Transfusion|September 12, 2018
Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemiaLaura C Alva, Ulrike Bacher, Katja Seipel, et al.
Hemasphere|November 15, 2019
Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML PatientsBianca R Schnell, Katja Seipel, Ulrike Bacher, et al.
Biomedicines|July 27, 2024
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid LeukemiaDanaë Martinez Flores, Dilara Akhoundova, Katja Seipel, et al.
BMC Cancer|April 15, 2023
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patientsDilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, et al.
Developmental Biology|March 22, 2003
Evolutionary aspects of developmentally regulated helix-loop-helix transcription factors in striated muscle of jellyfishPeter Müller, Katja Seipel, Nathalie Yanze, et al.
Leukemia & Lymphoma|August 22, 2015
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicityBeatrice U Mueller, Sandra Keller, Katja Seipel, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Molecular Cancer Therapeutics|July 25, 2015
Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal CancerMeera Raja, Matt Zverev, Katja Seipel, et al.
Cancers|January 21, 2023
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple MyelomaSelina Bühler, Dilara Akhoundova, Barbara Jeker, et al.
British Journal of Haematology|September 13, 2014
Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemiaDana Wetzel, Beatrice U Mueller, Behrouz Mansouri Taleghani, et al.
Cancers|May 14, 2025
Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma PatientsLea Jasmin Kündgen, Dilara Akhoundova, Michele Hoffmann, et al.
Transfusion|September 12, 2018
Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemiaLaura C Alva, Ulrike Bacher, Katja Seipel, et al.
Hemasphere|November 15, 2019
Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML PatientsBianca R Schnell, Katja Seipel, Ulrike Bacher, et al.
Biomedicines|July 27, 2024
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid LeukemiaDanaë Martinez Flores, Dilara Akhoundova, Katja Seipel, et al.
BMC Cancer|April 15, 2023
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patientsDilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, et al.
Developmental Biology|March 22, 2003
Evolutionary aspects of developmentally regulated helix-loop-helix transcription factors in striated muscle of jellyfishPeter Müller, Katja Seipel, Nathalie Yanze, et al.
Leukemia & Lymphoma|August 22, 2015
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicityBeatrice U Mueller, Sandra Keller, Katja Seipel, et al.
Pageof 8